Lisocabtagene Maraleucel: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), AOTMIT (Poland) and DMC (Denmark), among others, recommended or restricted lisocabtagene maraleucel, while CIPM (Spain) did not recommend it.
Assessment has run over 5.2 years, from 12 May 2021 at CHUIKYO (Japan) to 26 Aug 2026 at ZIN (Netherlands).
NYE METODER (Norway) changed its position: not recommended on 8 Feb 2026, recommended by 26 Apr 2026, after a resubmission.
No assessment is on file from PBAC (Australia), SMC (Scotland), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for lisocabtagene maraleucel, 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 25 of 27 records date from 2023 or later.
7 distinct indication wordings are recorded for lisocabtagene maraleucel by the agencies that label one in English (AWMSG and NICE).
CHUIKYO (Japan) was first to assess lisocabtagene maraleucel, on 12 May 2021; NYE METODER (Norway) did not open a file until 8 Feb 2026 — a wide spread of 4.8 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 5 years in total.
8 of the 11 agencies here assessed lisocabtagene maraleucel more than once, NICE (England) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for lisocabtagene maraleucel.
The full ledger for lisocabtagene maraleucel reads 11 recommended, 3 restricted, 3 deferred to NICE and 3 no benefit, with 7 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NICE (England) | 20 Aug 2026 | NICE TA1186 | terminated appraisal | source |
| G-BA (Germany) | 4 Jun 2026 | Breyanzi — benefit assessment §35a | added benefit: not proven | source |
| HAS (France) | 3 Jun 2026 | Re-assessment following post-listing study results | SMR substantial · ASMR III | source |
| AWMSG (Wales) | 1 May 2026 | Treatment of relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments | excluded, NICE appraised | source |
| NYE METODER (Norway) | 26 Apr 2026 | Behandling av voksne pasienter med diffust storcellet B-celle lymfom (DLCBL), høygradig B-celle lymfom (HGBCL), primært … | not introduced | source |
22 further decisions for lisocabtagene maraleucel, across 11 agencies, are not shown here. They include the most recent record on file, 26 Aug 2026 from ZIN (Netherlands); its outcome is in the subscriber dataset. They link to 20 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 27 decisions for lisocabtagene maraleucel from 11 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.